Indian companies stay put in Russia but pharma exports could be hit

By Krishna N. Das and Sumit Khanna

NEW DELHI (Reuters) -Indian pharmaceutical major Dr. Reddy’s Laboratories Ltd said on Wednesday it was focused on business continuity in and around Russia, as Indian drug exporters brace for temporary disruptions to sales due to the Ukraine crisis.

No Indian company has publicly withdrawn from Russia and New Delhi has declined to condemn Moscow’s invasion of Ukraine, despite pressure from the United States to do so. Western companies such as McDonald’s, PepsiCo, Coca-Cola and Starbucks have stopped sales of their best-known products in Russia.

“We have had a presence in the region for over three decades,” a Dr. Reddy’s spokesperson said in an email.

“Ensuring the well-being of our staff is our first and foremost priority, along with measures to meet patient needs and business continuity. Overall, we are monitoring evolving developments closely and preparing accordingly.”

It declined to say if it would raise or scale back investments in Russia, which accounted for more than 8% of its total sales of 189.7 billion rupees ($2.47 billion) in the last fiscal year that ended on March 31.

Dr Reddy’s, India’s fourth-biggest pharmaceutical company by market value, sells pain killers and other medicines in Russia. It is the main distributor in India for Russia’s Sputnik COVID-19 vaccines.

Executives at Indian pharma companies Torrent Pharmaceuticals and Zydus Lifesciences said they saw little or no impact on sales due to the Ukraine conflict.

But the Indian Drug Manufacturers’ Association (IDMA) told Reuters that prices of raw materials derived from benzene or other petroleum products would rise due to the war, and pharmaceutical exporters would have to seek buyers elsewhere.

“Overall demand for medicines will not go down, but there may be a temporary disruption,” said IDMA President Viranchi Shah.

“The problematic thing is managing payments from Russia” because of Western sanctions. “It will take some time to be addressed as an alternate mechanism will be required to be put in place,” he said.

An Indian government official, who declined to be named, said the country was confident of finding alternative markets for its pharmaceutical industry if needed.

At $173.7 million, pharmaceuticals accounted for 30% of India’s total exports to Ukraine between April and December last year. Sales to Russia during the period reached $386 million, or 15% of the total shipments to the country.

The Indian embassy says there are an estimated 300 Indian companies in Russia, most of them involved in trading tea, coffee, tobacco, pharmaceuticals, rice, spices, leather footwear, granite, I.T. services and garments.

($1 = 76.8050 Indian rupees)

(Reporting by Krishna N. Das; Editing by Raju Gopalakrishnan and Louise Heavens)

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor